Fig. 2: REZPEG-induced pharmacokinetics and pharmacodynamics. | Nature Communications

Fig. 2: REZPEG-induced pharmacokinetics and pharmacodynamics.

From: The regulatory T cell-selective interleukin-2 receptor agonist rezpegaldesleukin in the treatment of inflammatory skin diseases: two randomized, double-blind, placebo-controlled phase 1b trials

Fig. 2

REZPEG concentration in a, PsO and b, AD patients, shown as mean ± SEM. CD25bright Tregs measured in c, PsO and d, AD patients. CD4 + T cells in e, PsO and f, AD patients. CD8 + T cells in g, PsO and h, AD patients. All measurements performed using peripheral blood samples from patients treated with placebo (grey circles), 12 μg/kg (blue circles) or 24 μg/kg (red circles) REZPEG administered once every 2 weeks for 12 weeks. Pharmacodynamic data shown as mean fold change from baseline ± SEM. Number of samples at each time point provided in Supplementary Tables 6 (PsO) and 7 (AD). AD atopic dermatitis; PsO psoriasis; SEM standard error of the mean; Tcons conventional T cells; Tregs regulatory T cells. Source data are provided as a Source Data file.

Back to article page